Compare WEAV & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 441.5M |
| IPO Year | 2021 | 2006 |
| Metric | WEAV | VNDA |
|---|---|---|
| Price | $6.84 | $8.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $12.20 | ★ $13.63 |
| AVG Volume (30 Days) | 1.4M | ★ 2.7M |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,790,000.00 | $212,074,000.00 |
| Revenue This Year | $19.22 | $12.01 |
| Revenue Next Year | $15.10 | $24.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | 11.12 |
| 52 Week Low | $5.64 | $3.81 |
| 52 Week High | $17.63 | $9.60 |
| Indicator | WEAV | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 60.98 |
| Support Level | $6.48 | $7.14 |
| Resistance Level | $7.32 | $7.82 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 30.20 | 68.29 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.